Drug Trial Radar · NCT04390399
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
328
Planned (sponsor's estimate)
Start
Jul 21, 2020
Primary completion
Oct 13, 2025
Study completion May 31, 2027
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, three-cohort (2 randomized and 1 single-arm), open-label study to evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with aldoxorubicin HCl, N-803, and PD-L1 t-haNK in subjects with locally advanced or metastatic pancreatic cancer. Each treatment setting (ie, first line maintenance, second line, or third line or greater) will be evaluated independently as a separate cohort.
Conditions
- Pancreatic Cancer
Interventions
N-803Biological
Recombinant human super agonist interleukin-15 (IL-15) complex
Aldoxorubicin HClDrug
Aldoxorubicin hydrochloride
PD-L1 t-haNKBiological
PD-L1 t-haNK suspension for infusion
Nab-paclitaxelDrug
Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
GemcitabineDrug
2', 2'-difluoro 2'deoxycytidine, dFdC
CyclophosphamideDrug
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
5-FluorouracilDrug
5-fluoro-2,4 (1H,3H)-pyrimidinedione
LeucovorinDrug
L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
SBRTProcedure
Stereotactic Body Radiation Therapy
Irinotecan liposomeDrug
Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano\[3',4':6,7\]-indolizino\[1,2-b\]quinolin-9-yl-\[1,4'bipiperidine\]-1'-carboxylate, monohydrochloride, trihydrate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: 8 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Chan Soon-Shiong Institute for Medicine
El Segundo, California
Hoag memorial Presbyterian Hospital
Newport Beach, California
Astera Cancer Care
East Brunswick, New Jersey
Avera Cancer Institute
Sioux Falls, South Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.